We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
ESSA Pharma Inc | NASDAQ:EPIX | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.01 | 0.19% | 5.15 | 5.14 | 5.64 | 5.15 | 5.15 | 5.15 | 465 | 14:37:19 |
SOUTH SAN FRANCISCO, Calif. and VANCOUVER, BC, July 8, 2024 /PRNewswire/ - ESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that the Company will present at the JonesHealthcare Seaside Summit on Monday, July 15, 2024 at 11:00 a.m. PT.
David R. Parkinson, President and Chief Executive Officer, will host the presentation and will also participate in a panel discussion titled "Innovations and Challenges in Prostate Cancer" at 9:00 a.m. PT.
A live webcast of the presentation can be accessed in the Investors/Events & Presentations section of ESSA's website at www.essapharma.com. Following the event, the webcast will be archived on the ESSA website for 90 days. The panel, "Innovations and Challenges in Prostate Cancer," will not be webcast.
About ESSA Pharma Inc.
ESSA is a clinical-stage pharmaceutical company focused on developing novel and proprietary therapies for the treatment of patients with prostate cancer. For more information, please visit www.essaphrma.com, and follow us on X and LinkedIn.
Contacts
ESSA Pharma Inc.
Peter Virsik, Chief Operating Officer
778.331.0962
pvirsik@essapharma.com
Investors and Media:
Argot Partners
212.600.1902
essa@argotpartners.comĀ
View original content:https://www.prnewswire.com/news-releases/essa-pharma-to-present-at-the-joneshealthcare-seaside-summit-302190883.html
SOURCE ESSA Pharma Inc
Copyright 2024 PR Newswire
1 Year ESSA Pharma Chart |
1 Month ESSA Pharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions